Sign Up Today and Learn More About Escient Pharmaceuticals Stock
Invest in or calculate the value of your shares in Escient Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Escient Pharmaceuticals Stock
Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.
About Escient Pharmaceuticals Stock
Founded
2018
Headquarters
San Diego, CA, US
Industries
Messaging and Telecommunications, Content and Publishing, Sports
Escient Pharmaceuticals Press Mentions
Stay in the know about the latest news on Escient Pharmaceuticals
Incyte’s $750 Million Acquisition of Escient Pharmaceuticals
globallegalchronicle • Apr 29, 2024
Primary Biliary Cholangitis Market to Register Stunning ...
finance • Jan 28, 2024
Escient Pharmaceuticals patent describes MRGPRX2 antagonists
bioworld • Oct 25, 2023
Escient Pharmaceuticals Announces $120 Million Series C Financing
biospace • Nov 28, 2022
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires
biospace • Nov 23, 2022
Escient Pharmaceuticals Management
Leadership team at Escient Pharmaceuticals
Vice President, Finance and Administration
James R. Schmidt
Board Director
Kathleen Sereda Glaub
Join now and verify your accreditation status to gain access to:
- Escient Pharmaceuticals Current Valuation
- Escient Pharmaceuticals Stock Price
- Escient Pharmaceuticals Management
- Available deals in Escient Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Escient Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Escient Pharmaceuticals Revenue and Financials
- Escient Pharmaceuticals Highlights
- Escient Pharmaceuticals Business Model
- Escient Pharmaceuticals Risk Factors
- Escient Pharmaceuticals Research Report from SACRA Research
Trading Escient Pharmaceuticals Stock
How to invest in Escient Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Escient Pharmaceuticals through EquityZen funds. These investments are made available by existing Escient Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Escient Pharmaceuticals stock?
Shareholders can sell their Escient Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."